Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China
· Delayed Price · Currency is CNY 12.42
+0.18 (1.47%)
Mar 10, 2026, 3:04 PM CST
SHE:301211 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Net Income | 37.82 | 91.55 | 176.12 | 125.79 | 121.65 | 168.07 | Upgrade
|
| Depreciation & Amortization | 25.43 | 25.43 | 21.66 | 21.76 | 19.37 | 18.19 | Upgrade
|
| Other Amortization | 0.29 | 0.29 | 0.1 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | -0.18 | -0.04 | 0.07 | 0.03 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.11 | 0.11 | 2.58 | 0.66 | 0 | 0.35 | Upgrade
|
| Loss (Gain) From Sale of Investments | -19.03 | -19.03 | -4.02 | - | -10.7 | -5.59 | Upgrade
|
| Provision & Write-off of Bad Debts | 0.07 | 0.07 | -0.6 | -1.72 | 1.02 | 0.43 | Upgrade
|
| Other Operating Activities | 21.88 | -1.76 | -3.5 | -4.59 | 4.42 | 4.99 | Upgrade
|
| Change in Accounts Receivable | 1.27 | 1.27 | 49.31 | 31.65 | -61.53 | 13.51 | Upgrade
|
| Change in Inventory | 35.95 | 35.95 | -59.1 | -25.21 | 45.09 | -60.49 | Upgrade
|
| Change in Accounts Payable | -39.44 | -39.44 | -46.29 | 100.9 | 3.92 | -17.73 | Upgrade
|
| Operating Cash Flow | 65.98 | 96.07 | 137.06 | 250.79 | 123.98 | 121.67 | Upgrade
|
| Operating Cash Flow Growth | -35.96% | -29.91% | -45.35% | 102.28% | 1.90% | -67.32% | Upgrade
|
| Capital Expenditures | -87.6 | -164.43 | -186.53 | -75.95 | -21.07 | -13.39 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.07 | 0.09 | 0.47 | 0.06 | 0.01 | 0.06 | Upgrade
|
| Investment in Securities | 102.03 | -949.58 | -21.4 | -103.98 | 240 | 57.68 | Upgrade
|
| Other Investing Activities | 7.99 | 4.45 | - | - | 10.7 | - | Upgrade
|
| Investing Cash Flow | 22.5 | -1,109 | -207.47 | -179.86 | 229.65 | 44.35 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | - | 60 | Upgrade
|
| Long-Term Debt Repaid | - | - | - | -1.33 | - | -80 | Upgrade
|
| Net Debt Issued (Repaid) | - | - | - | -1.33 | - | -20 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 1,416 | - | Upgrade
|
| Common Dividends Paid | -72 | -138.24 | -96 | -72 | - | - | Upgrade
|
| Other Financing Activities | -2.45 | -1.63 | -1.17 | -4.06 | -11.02 | -103.37 | Upgrade
|
| Financing Cash Flow | -74.45 | -139.87 | -97.17 | -77.39 | 1,405 | -123.37 | Upgrade
|
| Foreign Exchange Rate Adjustments | 1.04 | 2.07 | 3.81 | 4.93 | -4.42 | -2.76 | Upgrade
|
| Net Cash Flow | 15.08 | -1,151 | -163.76 | -1.53 | 1,754 | 39.89 | Upgrade
|
| Free Cash Flow | -21.61 | -68.36 | -49.47 | 174.84 | 102.92 | 108.28 | Upgrade
|
| Free Cash Flow Growth | - | - | - | 69.89% | -4.96% | -68.15% | Upgrade
|
| Free Cash Flow Margin | -5.02% | -15.33% | -7.46% | 33.96% | 19.04% | 18.26% | Upgrade
|
| Free Cash Flow Per Share | -0.05 | -0.17 | -0.12 | 0.42 | 0.33 | 0.34 | Upgrade
|
| Cash Interest Paid | - | - | - | - | - | 2.28 | Upgrade
|
| Cash Income Tax Paid | 8.41 | 8.79 | 32.92 | 8.73 | 32.4 | 29.73 | Upgrade
|
| Levered Free Cash Flow | -15.2 | -93.94 | -118.8 | 102.2 | 64.84 | -39.97 | Upgrade
|
| Unlevered Free Cash Flow | -15.04 | -93.75 | -118.61 | 102.42 | 64.84 | -38.54 | Upgrade
|
| Change in Working Capital | -0.59 | -0.59 | -55.1 | 108.93 | -11.85 | -64.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.